Podcasts about biomed

Biola Folorunso tells PJ that seeing people like her was important in giving her the confidence to become a Biomed student. iWish 2026 Feb 5th at the RDS see here iwish.ie Hosted on Acast. See acast.com/privacy for more information.

Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They're passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We'll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Orange BioMed here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com    Episode transcript:   Stacey Simms  00:05 Today on diabetes connections, making the case for a better at home A1C test. Orange biomed is developing a compact, one drop device that they say could make frequent A1C checks easier and more accessible. They're sharing research that four A1C tests a year can lead to a nearly 4% reduction in A1C levels, but they say a lot of people can't get to the clinic that much. We'll talk about why this matters, even in the era of CGM, how the device works and what the early clinical trial results look like.   This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider.   Welcome to a bonus episode of diabetes connections. I hope your December is going well and that you know somehow you're able to take some time for yourself in the middle of all the holiday rushing around this time of year can be magical and stressful and exhausting and wonderful, and you know, all the things. And it's the same thing over here, super busy getting all this stuff done before the end of the year. Love it. But, you know, getting podcast episodes out, writing all the things we write and planning for next year, as they say, We're staying booked and busy.   But quick behind the scenes here to better explain this episode, I taped this interview way back over the summer during the ADA Scientific Sessions conference. I had some technical problems. I actually thought I lost this interview. There were two interviews that seemed to have gone missing. We're going to air the other one very soon. But thankfully, I do have backups upon backups. So all the info that you're going to hear today is still relevant.   This product, a small A1C test, is still in development. The only dated bit is about their follow up event that took place in August. Orange Biomed was launched in 2021 in South Korea, with its US headquarters in Providence, Rhode Island. Its founders are two Duke University alums, and they're my guests, CEO Yeaseul Park and Co-President Unghyeon Ko, We are also joined by Janice Dru-Bennett. She is a senior advisor at the company. Now, English is not the first language of two of these three speakers. This is a good time to remind you that most podcasting platforms have pretty good transcription services these days, especially Apple, I think they have a fantastic real time transcription service for podcasts that has been impressive to me in how they translate diabetes language. They're getting better at it. But I am also going to put a transcript of the interview in the show notes, which I don't normally do because the podcast services have gotten so good at it, but I think it could be helpful for at least a few of you out there. Okay, here is my conversation from the floor of ADA from the team at Orange biomed.   Yeaseul Park, Janice Drew Bennett and Dr Ko, Welcome to diabetes connections. I can't say live from ADA, because we're taping this to air later, but you're all there. Thank you so much for joining   Yeaseul Park  03:08 me. Yes, thank you. We're   03:10 excited to be here. Oh   Stacey Simms  03:11 my goodness. Can I ask first, how is the trip? I mean, yes, let me ask you. You guys came a long way.   Yeaseul Park  03:17 Yeah, it was 13 hours from Korea. But it's I'm so excited, because this event is really one of the times, and this is actually our third time attending ADA.   Stacey Simms  03:31 That's great. And we have so many questions for you, but Janice, let me ask you, you're there as everybody's setting up at the kind of beginnings of the show. What is it like right now for people who aren't familiar with ADA,   Janice Dru-Bennett  03:42 yes, you can hear the hammers in the background, although, but not on this podcast, but there's a lot of noise and people walking by. We're just setting up this the day before the exhibit hall opens and Dr Cole will be presenting at the Innovation Hub tomorrow, which is where we're sitting right now, with tables of innovators will be showcasing their diabetes innovations, and   Stacey Simms  04:04 there's a lot to get to. Dr Koh, I know you're presenting, but yes, let me ask you, like, what why? I know you said it's your third year, but why is orange biomed at ADA, what is your goal   Yeaseul Park  04:16 for us? ADA, is for a learning experience. As well as a platform to share. We come to see how all those around the world are fighting against diabetes, whether through clinical research, digital tools or technologies or community programs. At the same time, you're so proud to hear what orange biomat is building anytime, and eight months exhausting. That makes diabetes monitoring not accessible, not so many. And this year is especially exciting because Dr ko our co founder of orange buying at the group of speaking at ADA brand new program the innovation Hall.   Stacey Simms  04:58 That's awesome. So Dr Koh, tell me. Little bit about this, the Innovation Hub is pretty cool, but what are you going to be talking about?   Unghyeon Ko  05:05 Yeah, actually, I'm talking about the engineering part. I mean our technology, so our orange biomed, we are trying to solve a simple but a serious problem about the A1C accessibility. So to increase the A1C accessibility. So we are, we are developing at home device to measure the A1C level. So I'm, I'm talking about how difficult to increase the accessibility of A1C, but our technology is handled that difficult problem. So we now he's so agreed. So I'm going to introduce our technology and emphasize the importance of the A1C measurement at home.   Stacey Simms  05:49 Yeah, so A1C, it's interesting. My son was diagnosed at two, and in the pediatric world, you know, they'll just prick a finger generally and have that A1C right away. But my husband lives with type two, and he gets his labs drawn. And then it takes forever. So tell me a little bit before we go further about what you're hoping to do and making this easier for the patient,   Speaker 1  06:10 the frequent monitoring of A1C is so important to prevent the diabetic complications. So the money, so if you there is some so I can say that there is a research that if you measure the A 1d the four times a year, the People's A1C level is decreased like 3.8% but if you measure the A 1d at one per year, Then the A1C level is increased 1.5% so the frequent A1C monitoring is so important to prevent the diabetes complications. But problem is A1C measurement is only available at clinical site at this moment, so most of the A1C monitoring is done by the clinical side. So that's why people are difficult to monitoring A1C, because they have to visit the clinics forever. So is so like four times, or even eight times visit the clinics or hospital is quite difficult, especially in the people living in the far area from the hospital. So that's why the home A1C test is required. So I think that's why the accessibility of the A1C is one of the important things in managing the diabetes complications.   Stacey Simms  07:39 Dr Koh, is there evidence that, I mean more frequent A1C testing, I think would give many people peace of mind, perhaps. But is there evidence that it really does help in your health?   Speaker 1  07:51 Oh, yes, it is actually like from there is the research, like the famous research about the A1C level, like the research name this t and this research proved that the A1C is the one of the strongest predictor of diabetes complication. So A1C is completely related with the risk of diabetes complication. So like keeping A1C on the 7% dramatically lower the risk of diabetes complications. And also, there is another research in UK, the UK PDS study, and that study said they are A1C. Lowering A1C by just 1% can reduce overall mortality by 15% and microvascular complication by 37% so the roaring A1C is the goal of the treatment of the   Yeaseul Park  08:47 diabetes. So   Stacey Simms  08:48 when I think of at home diabetes tests, blood tests, seem like they're they're really sensitive, right? You have to be very careful with things like that, although we do, we did finger sticks at home for years and years. Are there challenges with at home A1C testing that that people like me could mess up,   Yeaseul Park  09:06 sure actually when I was doing pandemic outside system? So it's a new   Yeaseul Park  09:19 box of mustard with five or six needles inside, and we need to collect this blood to sound the left result. But then I really tried to collect the requirement matter blood, which is like it was like bleeding. Oh, it's not just retiring in one block, one drop of block, but it's like you need to try, yeah, many times, not just in one spot, to collapse in the block. And the other way you. Built female in, built a lot more broadly, to store your venous blood, and that's features like discomfort.   Stacey Simms  10:10 Would you mind taking us through your experience with the A1C testing? You were talking about how much blood it took? Yeah.   Yeaseul Park  10:17 So it, it requires many, many drops of blood. So I felt like it's like bleeding, and you make a lot of mess around the table. And so I felt, even though it's it was a topic time it was pandemic. So that's the only option I had at that time, but I wanted to make it simple and easier. And the other types of point of care devices only use a drop of blood still have some limitations, because we all don't want to bleed too much, so sometimes we try to finger stick very small and just squeeze to get enough blood. But if you squeeze to get enough sample volume, that's make your other liquid, like sweats, can also mix with your blood, and that actually affects the accuracy of the testing usually so many point of care devices also not recommend you to squeeze to get enough blood, so that means you need to treat a little too deep to get enough. So we really wanted to make this whole process or simpler and more problem.   Stacey Simms  11:43 Can you share a little bit about what the device looks like, what the patient experience is when they use it?   Speaker 1  11:48 Dr, CO, so our device is a palm size. Is in most like, like self, self poem, so it's a palm size device. So our device has no switch, but there is only a slider in the front of the device. So if you slide that, you can the device is turned on and you can insert the cartridge, and the cartridge is disposable cartridge. So after that, you just collect your blood and dilute it in the collecting tube and drop the sample into the cartridge, then analyze the A1C like automatically. So it's quite similar with the covid by covid test kit. So the covid test kit collect the sample in your nose and mix with the Rickett and drop it right? And it's quite similar.   Stacey Simms  12:45 So do you do a finger stick to put on the cartridge? How much blood to yells? Point, you know? How much blood do you need?   Speaker 1  12:52 Our devices for home use device, so it's quite we use a very different technology, because our device analyze the red blood cell one by one. So actually, we don't need exact unlike like five micro or 10 micro, we don't need the exact sample block. So we just need one drop of blood. So if the one drop is big, or if the one drop is right or small, it's fine for us. So one drop of blood, mix with their sample and drop one drop onto the cartridge. So maybe you can, you can drop one more than one drop, but we recommend one drop. So one drop of blood sample my dinner the rest yesterday pointed out that the skeezing the finger of blood is a problem for other device because, because in our body, there is a body wicked inside your under, under your skin. So if the body wicked is mixed with the blood samples, so it might be a problem because it dilute the blood sample. But our device, we analyze the Red Cross itself. So if it is diabetes, I think so we will find so you just puncture very best, and if you scale it, and it's totally fine for us. So it's, it's one of the good point of our device.   Yeaseul Park  14:20 How long does it take to get the results? It takes like, five minutes. Okay, yeah, and that's all at home. Yeah. Yezel, who do you see using this? Who is this for? Basically, it's for everyone. I think whoever has pre diabetes, diabetes type one, type two, and especially, I think who has limited access to primary care or lab testings. You know, many people who are older, tends to have more, especially the people who has limited access to primary care or lab testings. We believe this device can give more value to them. Yeah, and especially some people who have limited mobility, if they are older, or if they have experienced that amputation or something like that, they cannot go to the hospital by themselves. They need a caregivers to drive them to the hospital for the simple lab testing. But now I think it empowers patients who has that limitation still can take control their health by using this kind of home use device. How accurate   Stacey Simms  15:33 is it? I assume you have studies, and you've done some trials on how on the accuracy?   Yeaseul Park  15:37 Dr, CO, do you want to add that?   Speaker 1  15:40 Oh, yeah. So we are preparing the clinical trial. So the official clinical trials will be done within this year, but so that's our plan. But we we tested our device already using the in in last year. So last year, feasibility studies show that our device is quite similar with other point of care devices, and hopefully because at that time, our device, our especially our cartridge sensor, we just manufacturing our own like our in our lab. So this time, the official clinical trial in in this year, we are going to manufacturing in the factories so it might be more precise. So we hopefully we trying to chase the hospital accurate.   Stacey Simms  16:30 And I have to ask, where more and more people with diabetes are wearing a CGM and looking at time and range. What would you say to people who would tell you, well, we don't really need A1C anymore. We have time and range. Dr Cody, I see you nodding. Go ahead, yeah, yeah.   Speaker 1  16:47 So that's a very important point, but because the timing range is also important, and the CGM is very great technology for diabetes people. But problem is, like the A1C and C GM target different, like the CGM target the hypothesemia, but the A1C targeting the diabetes complications. So like, if you measure the timing range and you can manage your average glucose more nicely, but it might be prevent your hypothenia. But if you want to assess your diabetes management, you might be measure A1C. So if you measure timing range, but you also have to measure the A1C. So A1C is for everyone's and so. And also, the point is, if you don't treat the insulin, or if you don't treat the any medications, then you don't need to actually using the CGM, that's the ADH recommendation. So, but in in that case, you need the A1C as well. So A1C for everyone, and the CGM is for the people who treated the insulin. That's the ADA guide, right? And then,   Stacey Simms  18:12 yes, let me just ask you. You know, you came all this way. As you say, this is your third time at ADA. Trials are starting soon. What's your hope here? Is this something you see in homes of everyone who has any kind of diabetes? What's the big goal for Orange biomed?   Yeaseul Park  18:28 Every time we talk to a day, we can feel what's going on here in diabetes industry. It's a huge maybe first year, I the most frequently hard keyword was aid system. But after that, we now have GLP one, and now we hear more keyword around obesity. So that's a little slightly different trend I can feel. And once you come and join this full sessions, then I can see there's make everyone is making a progress, and we are all together. Want to fight against diabetes in their own way or with their own expertise, whether it's pharmaceutical, whether it's medical device or diabetes, sex, sometimes any other community programs that really support this patient and families, the community, and it's Really this whole atmosphere actually really motivates our team and myself, and we can feel the value. I can really feel this we are doing something valuable to patients and our community, and that's the most great thing, like the greatest thing that I can take when I come back to home with a. After the ADA. And for sure, we want to have opportunity to make voice what we are doing at Orange biomed, and want to deliver this value to the patient and other healthcare professionals. Otherwise, even though we are working hard to make this progress, no one knows, and that makes any changes the world. So that's the important purpose we are coming here. That's great.   Stacey Simms  20:30 Janice, before I let you all go, I know you wanted to talk about an event you've got coming up in Chicago. Can you tell me a little   Janice Dru-Bennett  20:37 bit about that? Yes, we're really excited for Orange biomed to be hosting the first map your health event, a local event here in Chicago, we have done a solving healthcare challenges webinar to announce our map your health campaign, which is, monitor your A1C, monitor your health and then adapt your treatment and prevent chronic disease. And we're actually going to be hosting on August 16, from 10am to 3pm in Chicago at their humble Park, Health Wellness Center, the first local event, inviting all local partners. We'll have some virtual sessions, showcase with yoga or ask the endocrinologist. So we'll have a very exciting agenda that both virtual and on site participants can join in, eat healthy foods. See, see what's in Chicago from a screenings perspective, and really get people motivated to map your health. So hashtag, map your health. Tell your your your health story, and let's get everyone, um, healthier. Wow.   Stacey Simms  21:35 Okay, fantastic. Well, yes, I'll park Dr co Janice, thank you so much for joining me. Have a terrific show. I know this is an audio podcast, but especially behind you. Yassil, it has been wild to watch the construction guys are going by and motorized carts and things are going up behind you. So have a wonderful ADA. Keep us posted, and we'll get the word out about your event in August and going forward. Thanks so much for joining me.   more information in the show notes about the studies and about orange biomed. You can sign up for alerts and emails from them as their product moves forward. So if you're interested, definitely check that out. Thank you to my editor, John Bukenis from audio editing solutions, thank you so much for listening. I'm Stacey Simms. I'll see you back here soon. Until then, be kind to yourself.   Benny  22:30 Diabetes Connections is a production of Stacey Simms media. All Rights Reserved, all wrongs avenged.    

Dr. Costas Karatzas, CEO, Director, and Co-Founder of Acesis BioMed, is focused on developing a novel treatment for low testosterone in men, an oral peptide that stimulates the body to restore its own natural testosterone production. The therapy's mechanism differs from current testosterone replacement therapies and avoids the side effect of infertility seen in younger men using traditional TRT, which shuts down natural hormone and sperm production. This low T condition is not just a function of aging but is increasingly affecting younger men due to lifestyle, environmental factors, and co-morbidities like diabetes and obesity. Costas explains, "Our mission is to revolutionize the treatment of low T, or male hypogonadism, and related comorbidities. Although we remain laser-focused on going in phase one with a low T application, because low testosterone is involved in many other diseases like type 2 diabetes, fatty liver disease, obesity, etc., we're also going to be co-developing those with partnerships initially with academia and later on with other pharma companies. So this is, in a nutshell, the short story about Acesis. The differentiation being everything else marketed provides the body with exogenous testosterone, whereas in our case, we teach the body to go back to its old memory and generate or restore its own testosterone in a natural way." "Men can develop low testosterone because of the aging process, but this is a wrong idea. Low testosterone is not just an aging problem. It's true that we as men lose testosterone from the age of 30, about 1-1.5%, which is circulating in our blood. By the time we reach sixties or seventies, we could have probably 50% to 60% of the testosterone levels we had while we were at the age of 30 years old. Globally, it's estimated that about 40% of adult men may have suboptimal testosterone levels, especially if you include men with other health issues like diabetes, and we mentioned obesity. So, for older men, this is a big demographic, and as the global male population ages, the number of men with low T is increasing. Interestingly enough, the FDA has only approved the current marketed products of testosterone for men who are between the ages of 30 and 65. Anything over 65 is considered a normal process of aging according to the regulators." #AcesisBioMed #HormoneHealth #TestosteroneReplacementTherapy #TRT #MensHealthAwareness #BiotechInnovation #EndocrinologyResearch #LowT #MensHealth #Testosterone #HormoneResearch #Menswellbeing #Andropause acesisbio.com Download the transcript here

Dr. Costas Karatzas, CEO, Director, and Co-Founder of Acesis BioMed, is focused on developing a novel treatment for low testosterone in men, an oral peptide that stimulates the body to restore its own natural testosterone production. The therapy's mechanism differs from current testosterone replacement therapies and avoids the side effect of infertility seen in younger men using traditional TRT, which shuts down natural hormone and sperm production. This low T condition is not just a function of aging but is increasingly affecting younger men due to lifestyle, environmental factors, and co-morbidities like diabetes and obesity. Costas explains, "Our mission is to revolutionize the treatment of low T, or male hypogonadism, and related comorbidities. Although we remain laser-focused on going in phase one with a low T application, because low testosterone is involved in many other diseases like type 2 diabetes, fatty liver disease, obesity, etc., we're also going to be co-developing those with partnerships initially with academia and later on with other pharma companies. So this is, in a nutshell, the short story about Acesis. The differentiation being everything else marketed provides the body with exogenous testosterone, whereas in our case, we teach the body to go back to its old memory and generate or restore its own testosterone in a natural way." "Men can develop low testosterone because of the aging process, but this is a wrong idea. Low testosterone is not just an aging problem. It's true that we as men lose testosterone from the age of 30, about 1-1.5%, which is circulating in our blood. By the time we reach sixties or seventies, we could have probably 50% to 60% of the testosterone levels we had while we were at the age of 30 years old. Globally, it's estimated that about 40% of adult men may have suboptimal testosterone levels, especially if you include men with other health issues like diabetes, and we mentioned obesity. So, for older men, this is a big demographic, and as the global male population ages, the number of men with low T is increasing. Interestingly enough, the FDA has only approved the current marketed products of testosterone for men who are between the ages of 30 and 65. Anything over 65 is considered a normal process of aging according to the regulators." #AcesisBioMed #HormoneHealth #TestosteroneReplacementTherapy #TRT #MensHealthAwareness #BiotechInnovation #EndocrinologyResearch #LowT #MensHealth #Testosterone #HormoneResearch #Menswellbeing #Andropause acesisbio.com Listen to the podcast here

Dr. Patrice Cuff has done many things! An industry postdoc, industry business development, and now an alternative academic role at a teaching institution. Learn more from Dr. Cuff about how she has pivoted and found job satisfaction on a unique journey to find the right fit. 

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

Dr. Jennifer Malinowski shares her role with Lab Corp and the work she does in Market Access. 

We're fascinated by the microbiome — and for good reason. But how do we protect this invisible ecosystem that plays such a vital role in our health?From engineering live, programmable therapeutics that disarm dangerous gut pathogens to creating a global “doomsday vault” to safeguard the diversity of human gut microbes, we dive deep into the cutting-edge science shaping the future of microbiome research.Show notes1. Ronda, C., Perdue, T., Schwanz, L. et al. Precise virulence inactivation using a CRISPR-associated transposase for combating Enterobacteriaceae gut pathogens. Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01453-12. 2. Dominguez-Bello, M.G., Steiger, D., Fankhauser, M. et al. The microbiota vault initiative: safeguarding Earth's microbial heritage for future generations. Nat Commun 16, 5373 (2025). https://doi.org/10.1038/s41467-025-61008-5

Dr. Matt Harlow, PhD, Senior Scientist at TRIANA Biomedicines, shares his path since Vanderbilt and his daily work life in drug discovery. 

Dr. Geben shares about her role as a consultant with Anchor Point Consulting, specifically in competitive intelligence. She also shares about her time working abroad, being 100% remote, and the opportunities she purused in grad school to land her current role. 

Dr. Shaver shares about his role at Natera as their Associate Director of Bioinformatics.

Dr. Santos tells us about her role as a consulting with a firm that focuses on competitive intelligence. She shares about her post-PhD path in industry while maintaining her love for science. 

In this eye-opening episode of Fertility Village Live, co-hosts Tanya and Erin welcome Dr. Mathieu Boilard, PhD—CEO and founder of Nasci Biomed—for an in-depth conversation on male fertility and the groundbreaking science happening behind the scenes. Nasci Biomed is a private research and diagnostic lab based in Quebec, Canada, specializing in the advanced cellular biology of spermatozoa. Their work uses cutting-edge flow cytometry and biochemistry to offer some of the most comprehensive male fertility analyses available today.Dr. Boilard walks us through what a fertility spermogram actually measures—from volume and pH to detailed mobility patterns, morphology, and even DNA fragmentation. He explains why these deeper insights matter when it comes to diagnosis, early detection of male factor infertility, and choosing the right course of treatment. We explore common diagnoses like oligospermia, azoospermia, and teratospermia, and discuss what current options exist for men with very low or no sperm—such as micro-TESE procedures and hormone treatments. We also talk about how testosterone and other hormones play a critical role in sperm production, and what signs men can look for if they're wondering whether they may have a fertility issue.We dig into sperm DNA fragmentation—what it is, how it's tested, and how it can impact outcomes for IUI and IVF. Dr. Boilard shares how Nasci is bridging the gap between fertility research and clinical application, constantly searching for technologies that could lead to meaningful breakthroughs for patients. Whether you're currently TTC, undergoing treatment, or just learning more about your reproductive health, this episode provides essential knowledge for anyone looking to better understand the often-overlooked male side of the fertility journey.To learn more about Nasci Biomed or to book an appointment for a fertility spermogram or DNA fragmentation test, visit: www.nascibiomed.ca

Dr. Keely Solomon Gilroy, PhD, shares her path from Medical Science Liaison to Science Communication to now a Medical Director in Industry. 

Dr. Emily Turner shares her career projection on the road to medical writing. 

This week on bigcitysmalltown, we examine the role of the Texas Biomedical Research Institute—better known as Texas Biomed—in San Antonio's scientific community, the rapidly changing landscape of research funding, and the challenges of combating misinformation in an era of political division.Host Bob Rivard is joined by Dr. Larry Schlesinger, president and CEO of Texas Biomed, for a conversation that touches on Dr. Schlesinger's personal background as the child of Holocaust survivors, his career as an infectious disease researcher, and his reasons for coming to San Antonio eight years ago. Together, they discuss how Texas Biomed has evolved during his tenure, including efforts to diversify funding, expand partnerships with the pharmaceutical sector, and increase the institute's prominence amid public health crises.They discuss:The critical importance of vaccines and ongoing education amid rising rates of vaccine hesitancy and misinformationHow Texas Biomed contributed to the early research and validation of animal models for COVID-19 vaccinesThe impact of recent federal policy changes on international collaboration and research funding for U.S. institutionsEfforts to modernize and expand the Texas Biomed campus, including the complexities around philanthropy and private sector engagementThe relationship between infectious disease and chronic illness—and what chronic disease research could mean for the future of public health in San AntonioThe episode offers context on the state of science in Texas, the pressures facing research institutes in the current political climate, and the ways that local scientific leadership can shape the future of public and community health.-- -- RECOMMENDED NEXT LISTEN:▶️ #106. Tom Slick's Legacy: The San Antonio Institution Studying Consciousness – Discover the fascinating roots of Texas Biomed through the story of Tom Slick, the visionary entrepreneur behind San Antonio's world-class science institutions.  

三腳貓很榮幸邀請到擁有5000+粉絲的臉書粉專「實驗鼠的七分鐘廢文」的實驗鼠來跟大家分享自己從博士班開始在粉專分享生活和實驗室裡的大小事（鬼故事）的契機，想更認識實驗鼠「阿鼠姊姊」嗎？想知道粉專名稱是怎麼來的嗎？想聽更多粉專裡面沒有講到的鬼故事嗎？那就絕對不要錯過這一集！ 工作人員 內容製作：實驗鼠的七分鐘廢文、若晴、Angel 剪輯：若晴 後製：若晴 文案：若晴 封面：雯薇 上架：若晴 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

When Gordon Groschl assumed the dual role of CISO & Director of Healthcare Technology Management at Texas Children’s Hospital eight months ago, part of his purview was one of the trickier (and fast evolving) niches of healthcare IT – biomedical equipment. Groschl, an 18-year veteran of the organization, now oversees a large network of over […] Source: Groschl Tightening Up Biomed Cyber at Texas Children's, Notes Communication Key to Success on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

Access the PHS Digital Coursebook here.Click here to see all of the Project Lead The Way course offerings at PHSVideo about Biomed ProgramTech Ed and Engineering Program videoMath and Computer Science and Cyber Security PLTW classes video 

From medicine to recruitment, property, and finally, the wild world of entrepreneurship... My journey has been anything but a straight line. And what better way to unpack it all than on a podcast with my good friend Sandi?We explored the winding road that led me to where I am today, including a deep dive into my obsession with productivity (essential for juggling all those passions!), how to stay focused while battling ADHD, and why understanding your own quirks is essential for success. But don't worry, it's not all serious talk! Get ready for some laughs, personal anecdotes, and maybe even a few embarrassing childhood stories. If you've ever wanted to learn more about the real me (and steal a few productivity hacks along the way), this episode is a must-listen! Hosted on Acast. See acast.com/privacy for more information.

When a critical device fails mid-surgery, there's only one team to call… Biomed! This week, we're joined by the Bearded Biomed himself, Chace Torres, as he reveals why keeping ORs running smoothly takes more than just maintaining equipment - it requires quick thinking, technical expertise, and partnerships that span all surgical teams. From preventive maintenance to emergency repairs, discover how biomed professionals are driving patient safety and surgical success by ensuring every device is ready when it's needed most. Ready to see surgery through the eyes of healthcare's tech experts? It all comes together in this can't-miss Season 27 finale – tune in here! Season 27 of Beyond Clean releases under the 1 Episode = 1 CE delivery model. After finishing this interview, earn your 1 CE credit immediately by passing the short quiz linked below each week. Visit our CE Credit Hub at https://www.beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits.  #BeyondClean #SterileProcessing #Podcast #Season27 #PlanetSurgery #Biomed #PreventiveMaintenance

A recent study in the journal Nature unveiled new proteins that can neutralize the deadliest of snake venoms. They're “new” in that they aren't found in nature—they were created in a lab, dreamed up by AI.Using AI to discover, or design, the building blocks of drugs is a fast-growing area of research. Another team of scientists out of Philadelphia is using AI to discover new antibiotics by resurrecting long-lost molecules from extinct species like neanderthals and woolly mammoths.We know what you're thinking: It sounds too sci-fi to be true.Flora Lichtman talks with two pioneers in the field about how AI is supercharging drug discovery: Dr. César de la Fuente, bioengineer and presidential associate professor at the University of Pennsylvania in Philadelphia, and Nobel laureate Dr. David Baker, director of the Institute for Protein Design and professor at the University of Washington in Seattle.Transcripts for each segment will be available after the show airs on sciencefriday.com.For our Los Angeles listeners: We're working on a story about the toxins left behind by the fires and we want to hear from you. How is this affecting you? Are you worried about the air and water and soil? How are you approaching clean-up? And what questions do you have?Leave us a voicemail at 1-646-767-6532 or send us an email at scifri@sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

What happens when the companies holding your most sensitive data start to falter? Sarah is joined by Drex to dive into the alarming challenges facing 23andMe and Atlas Biomed, two major players in genetic testing. Explore the intersection of data privacy, financial instability, and the unique risks of DNA testing. From data breaches to the ethical implications for health systems, this episode uncovers why the stakes are higher than ever for healthcare leaders. Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Drex delves into the challenges facing companies like 23andMe and Atlas Biomed, highlighting critical concerns around DNA data privacy and the impact of financial struggles on sensitive information. Learn actionable insights to tighten your organization's data agreements, ensure privacy compliance, and mitigate risks in the evolving cybersecurity landscape.Remember, Stay a Little Paranoid Subscribe: This Week HealthTwitter: This Week Health LinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Welcome back to another episode of Science of Slink! Today we are talking about how to stay motivated as a home poler. In this episode I talk about the most common motivation that men and women have for exercising, how home based exercise programs compare to center based programs, and how motivation can change depending on your age. I also talk through how to build self-efficacy as you are learning new skills on and off the pole. Whether you are new to pole or not, sometimes our motivation can change. Let's look together at the research behind it.  Sources: Al Kubaisy, W., Mohamad, M., Ismail, Z., & Abdullah, N. N. (2015). Gender Differences: Motivations for performing physical exercise among adults in Shah Alam. Procedia-Social and Behavioral Sciences, 202, 522-530. McDonagh, S. T., Dalal, H., Moore, S., Clark, C. E., Dean, S. G., Jolly, K., ... & Taylor, R. S. (2023). Home‐based versus centre‐based cardiac rehabilitation. Cochrane database of systematic reviews, (10). Schutzer KA, Graves BS. Barriers and motivations to exercise in older adults. Prev Med 2004;39:1056–61. Crystal N Steltenpohl, Michael Shuster, Eric Peist, Amber Pham, Joseph A Mikels, Me Time, or We Time? Age Differences in Motivation for Exercise, The Gerontologist, Volume 59, Issue 4, August 2019, Pages 709–717, https://doi.org/10.1093/geront/gny038 Al-Eisa, E., Al-Rushud, A., Alghadir, A., Anwer, S., Al-Harbi, B., Al-Sughaier, N., ... & Al-Muhaysin, H. A. (2016). Effect of motivation by “Instagram” on adherence to physical activity among female college students. BioMed research international, 2016(1), 1546013. This podcast is a production of Slink Through Strength, the inclusive, evidence-based online pole studio, which can be found online at Slink Through Strength dot com. Thanks for joining!

This is the Women of Influence Podcast series, delivering next level insights and expertise live from GlobeSt.'s Women of Influence Conference.The Women of Influence Podcast Series is an exclusive mini-series of The Crexi Podcast, an insider's look at all things commercial real estate, produced in collaboration with GlobeSt. The Crexi team visited Women of Influence and recorded in Lake Tahoe, California, from the floor of the conference, highlighting movers and shakers in commercial real estate. The Crexi Podcast explores various aspects of the commercial real estate industry in conversation with some of the top professionals in the space. In each episode, we feature different guests to tap into their wealth of CRE expertise and explore the latest trends and updates from the world of commercial real estate. In this episode, Crexi's Shanti Ryle sits with Julie Baird, President of First American Exchange Company, and Shayna Platt, Senior Director, ESG, at BioMed Realty, to cover wide-ranging topics, including:Introduction to the Crexi PodcastMeet Julie Baird: A Leader in Real EstateJulie's Career JourneyBuilding a Collaborative CultureChallenges and AchievementsMeeting People Where They AreCreating a Collaborative CultureAdvice for Young LeadersBuilding Trust and CollaborationChallenges and Opportunities for Women in LeadershipIndustry-Wide Efforts for DiversityConclusion and Contact InformationShayna Platt's Journey into ESGUniversity Influence and Early CareerRole at BioMed RealtyUnderstanding ESG in Commercial Real EstateChallenges in Implementing ESG PracticesGaining Internal Buy-In and EngagementPositive Outcomes and Executive SupportFuture Trends in Life Sciences Real EstateThe Importance of Accurate ESG DataAdvice for Young Professionals in ESGConnecting and Mentoring in ESGClosing RemarksAbout Julie Baird:Julie Baird is President of First American Exchange Company. She leverages people centered leadership practices to foster an organizational culture of collaboration, transparency, and trust, with employees reporting high job satisfaction while delivering record setting financial results.A fierce advocate for elevating female voices within the CRE industry, Julie has been a member of GlobeSt Woman of Influence speaking faculty since its inception and was awarded as a Woman of Influence in 2023; she was awarded First American's DPK Circle of Excellence Award in 2022, a recognition given to a very small number of the highest achieving employees in the entire organization of nearly 20,000 employees, and Julie was invited to participate in First American's Women in Leadership class of 2021 and selected by her class as a presenter to the First American Financial executive team.Julie is a past President of the Federation of Exchange Accommodators and is past Director for CREW Denver. She is a frequent speaker and author on 1031 exchange and industry related topics.Julie is a former Chair of the Executive Committee of the Real Property Law Section of the State Bar of California and she is the prior Managing Editor of the California Real Property Journal. In 2009, Julie was named as one of the "Top 20 Under 40" real estate professionals by the Commercial Real Estate Women (CREW) Network. Prior to joining First American, Julie was a real estate attorney in San Francisco.About Shayna Platt:Shayna Platt is the Senior Director of Environmental Social Governance (ESG) at BioMed Realty. A Blackstone Real Estate portfolio company, BioMed Realty is a leading provider of real estate solutions to the life science and technology industries. BioMed owns and operates high quality life science real estate comprising 15.9 million square feet concentrated in leading innovation markets throughout the United States and United Kingdom, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder and Cambridge, U.K. In addition, BioMed maintains a premier development platform with 2.5 million square feet of Class A properties in active construction to meet the growing demand of the life science industry.About GlobeSt. Women of Influence: The Women of Influence Conference is an exclusive two-day event that celebrates the women who drive the commercial real estate industry forward. These influential leaders will discuss the critical issues facing CRE now and in the future, what it means to be a woman in business today and how women CRE leaders can uplift and support each other on their journey to the top.  If you enjoyed this episode, please subscribe to our newsletter and enjoy the next podcast delivered straight to your inbox. For show notes, past guests, and more CRE content, please check out Crexi's blog. Ready to find your next CRE property? Visit Crexi and immediately browse 500,000+ available commercial properties for sale and lease. Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexi

In episode 112, host Jon Wood speaks with Michele McKinley about the unique possibilities for partnership between the Biomedical and Sterile Processing departments. McKinley addresses how to build this relationship, the opportunities and challenges of collaboration, and how critical this interaction is when considering the best interests and protection of patients. Earn CE Now

Dr. Amicia Elliott always knew she wanted to be an entrepreneur. But on the path, she collected tools for her entrepreneur toolkit to get her to where she is today: PhD training, tech transfer, government research, postdoc fellowship. Now she is the Product Director with Form Bio. Hear about all the steps in her path on the last episode of Season 7. 

Dr. Justine Sinnaeve, PhD, is an Associate Scientific Director at Ashfield MedComms and tells us about her experience graduating during COVID and how she utilized that time to work freelance before launching into her SciComm/Medical Writing role. 

After a successful internship with Health Research in Action, Lindsay Redman Rivera used her experience to pivot to a full-time position. She discusses what she learned during her PhD training as well as shares her approach to the two-body-opportunity.

After a fellowship with the FDA in regulatory, Dr. Todd Townsend, PhD, shares his path to his current role as the Regional Medical Scientific Director, Cardiovascular & Metabolism at Merck. 

References Dr Guerra: membrane lectures Balin, M.1966. "Coming Back to Me" Jefferson Airplane. Surrealistic Pillow.1967. https://youtu.be/y2f3tlgApHw?si=cTa1nhYw6kcycxUs Dylan (Zimmerman),R. 1962 "Girl from the North Country". w. Johnny Cash. https://youtu.be/Je4Eg77YSSA?si=eYXfJhwOQisGjPHW Schubert, F. 1828.Piano Sonata in B-flat major, D.960 https://youtu.be/lncNcNtGkJY?si=KRTh3hQStQ3x51Ug --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

References Biochimica et Biophysica Acta (BBA) - Biomembranes 2015. Volume 1848, Issue 3. Pages 805-812. J Immunol. 2018 Feb 1; 200(3): 915–927. Am J Rhinol Allergy. 2015 Jan-Feb; 29(1): 35–40. Corelli,A. 1714. Concerto in D Major Op. 6 No. 4, https://youtu.be/3smZkpqXYHs?si=uwEdDkRv-bz-zJXW --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

References J Immunol. 2018 Feb 1; 200(3): 915–927 Cells. 2020 Jan; 9(1): 198. Cells. 2022 Apr; 11(7): 1105 Nature Comm. 2020. volume 11, Article number: 35 Schubert F. 1829. Fantasie in F minor. D940 https://youtu.be/UyjzqPPXDcw?si=XW_SMP7j-Kza8pmq Winwood, Capaldi and Wood. 1967 (Traffic). "Dear Mr Fantasy" https://youtu.be/dyMiUmrouZU?si=1ZSdXupm3WFBAxTz --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

There is no typical day for co-founder and CEO of Infinimmune Wyatt McDonnell, PhD. Dive in to the whatnots and to-dos of starting and maintaining a company in this episode. 

References Clin Chim Acta . 2020 Sep:508:61-68 Applied Physiology, Nutrition, and Metabolism.2021. Volume 46, Number 8. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

The jump from academia to a start-up has been a fun one and we learn more as we sit down with Dr. Martin Moore, PhD, Chief Scientific Officer of Meissa Vaccines. 

In this episode of Medsider Radio, we had a riveting chat with David Hochman, founder and CEO of Orchestra BioMed, a company accelerating high-impact technologies through risk-reward-sharing partnerships with leading medical device companies.David has over two decades of experience in healthcare entrepreneurship, venture capital, and investment banking. He has a history of leading successful medical startups, including Orchestra Medical Ventures and Accelerated Technologies. As Chairman of Motus GI and former board member of Corbus Pharmaceuticals and PROLOR Biotech, David has been instrumental in advancing medical technologies, contributing to significant mergers & acquisitions, and many fundraising successes.In this interview he talks about driving successful partnerships, operational excellence in R&D, and the importance of a long-term strategy for sustainable industry innovation through aligned incentives. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with David Hochman.

References Front. Immunol., 21 August 2019 Sec. Cancer Immunity and Immunotherapy Volume 10 Front Immunol. 2021; 12: 640869 PLoS One. 2014; 9(2): e87523 Vivaldi, A. 1719. "L 'inverno". https://youtu.be/pCqO-0339k0?si=k5xtuT8x7SfJeLok --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

References Guerra-intermediary metabolic lecture archives ProcNatl Acad Sci U S A. 2014 Jun 17; 111(24): 8913–8918 Nutrition, Metabolism and Cardiovascular Diseases, 2023-09-01, Volume 33, Issue 9, Pages 1785-1796. Int J Cancer. 2019 Feb 1;144(3):533-544 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

What came first for Kristi Thiel: Co-Founder or Professor? Learn more about Dr. Thiel's interesting steps in her career path and all the great ideas that have helped her along the way. 

References Front Immunol. 2023; 14: 1151166 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Bo and the crew talk about the chances LSU wins the SEC West, the big renovations to MRA and what NFL coaches look like they would do outside of the NFL in the third hour of the show live in the BankPlus Studio. The guys break down ways the SEC West could shake up with Alabama at the top and the possibility of Ole Miss beating Georgia still seems bleak. Head of School at Madison-Ridgeland Academy Termie Land joins the show talking about the big advancements with the Patriots. Termie talks about the recent AP Honor Roll Gold Distinction the school received and how hard it is to reach that standard. Termie talks about how MRA puts a huge emphasis on professional development and how the new Bio-Med program will help students grow. Bo and Termie talk about the newest and upcoming renovations for MRA and what to expect in the future. In the SEC Insider Hit, Bo and the crew talk about what NFL coaches look like they would do for work if they weren't coaching live in the BankPlus Studio. The guys look at some of the most well known coaches in the NFL and talk about how someone like Cowboys coach Mike McCarthy would be doing balloon animals at a kids birthday party. Bo looks at the young prodigy coaches like Mike McDaniel and Kyle Shanahan and how they have completely different looks. One of the most decorated coaches in the NFL isn't safe from the comparison and Bo thinks that Robert Saleh for the Jets looks like the perfect kickboxing instructor. Out of Bounds is sponsored by BetterHelp. Visit BetterHelp.com/BOUNDS today to get 10% off your first month Learn more about your ad choices. Visit megaphone.fm/adchoices

Head of School at Madison-Ridgeland Academy Termie Land joins the show talking about the big advancements with the Patriots. Termie talks about the recent AP Honor Roll Gold Distinction the school received and how hard it is to reach that standard. Termie talks about how MRA puts a huge emphasis on professional development and how the new Bio-Med program will help students grow. Bo and Termie talk about the newest and upcoming renovations for MRA and what to expect in the future. Out of Bounds is sponsored by BetterHelp. Visit BetterHelp.com/BOUNDS today to get 10% off your first month Learn more about your ad choices. Visit megaphone.fm/adchoices

The Sunday Times' tech correspondent Danny Fortson brings on Ranit Aharonov to talk about this moment for artificial intelligence (3:15), studying the brain (6:30), Project Debater (8:30), neural networks (11:30), language's AlphaGo moment (14:50), the big idea at Pangea (19:20), getting it into the hands of doctors and drug communities (23:25), the role of AI in this tool (26:15), the regulatory limits (32:15), and why she didn't debate the AI she created (37:25). Hosted on Acast. See acast.com/privacy for more information.

TODAY ON THE ROBERT SCOTT BELL SHOW: Emord's Sacred Fire of Liberty, New Mexico governor outrage, Temporary Restraining Order Issued, Biden Impeachment Inquiry, Biden rambling in Vietnam, Ground Zero fact check, BioMed Expo, Toxic blood, Green cleaning warning, Mental health profits, Skin cancer options, Homeopathic Hit - Ignatia and MORE! http://www.robertscottbell.com/natural-remedies/emords-sacred-fire-of-liberty-new-mexico-governor-outrage-temporary-restraining-order-issued-biden-impeachment-inquiry-biden-rambling-in-vietnam-ground-zero-fact-check-biomed-expo-toxic-blood/

Tuvik Beker, CEO, and Ranit Aharonov, CTO of Pangea Biomed, have designed ENLIGHT, a computational platform driving precision oncology that matches cancer tumors with available therapies. Drawing on an understanding of synthetic mortality and synthetic rescue, this approach focuses on how the interaction between genes increases or decreases the tumor cell's fitness and the likely response to a drug. Determining which populations might benefit most from a drug opens the door to new treatments for common and rare diseases. Tuvik explains, "When we match therapies to patients, just according to the pure genetic characteristics of the tumor, sometimes we miss potential therapies, and sometimes we give patients therapies that do not work very effectively. To solve that, we developed ENLIGHT, which looks at the broader characteristics of the tumor, not just at the target gene, but multiple interactions, and that way, we can find potential therapies that are missed by the current guidelines and common biomarkers." Ranit elaborates, "So when we search for these interactions between genes, we look at a lot of available cancer data. We have a large database of a lot of cell lines that were treated and human tumors, and we know the survival of the patients and so on, but we don't need to know anything about what drugs they got. Our algorithms allow us, by looking at a lot of correlations between different activations of genes and survival and what happens to cells, we are able to find what are the pairs in the entire genome of genes that their co-activation affects the fitness or the tumor survival. And by knowing this, you can think of it as a sort of vulnerability map of tumors." "One of the things I haven't yet described and I think wouldn't have happened without this revolution is that we can now move a step further. When we look at a patient's tumor, we don't necessarily need to measure the RNA expression or the activation of genes directly. We can look at the tumor through a microscope using standard histopathology slides, the ones with the bluish and pinkish coloring that have been used for decades and are really available everywhere." #PrecisionsMedicine #Oncology #PrecisionOncology #RareDisease #Biotech #Startup #AI #MachineLearning pangeabiomed.com Download the transcript here

For this episode, I was joined by Brian DeHaven, PhD, inaugural chief program director for the College's Biomedical Sciences program. Dr. DeHaven joined PCOM earlier this year and has an ambitious agenda for the BioMed program. He and I discuss his vision for the program and what sets PCOM apart from its peers; changes to education as a result of the pandemic and the effort to meet students where they are; and the future of graduate medical education.

The FDA warns of a vulnerability affecting biomedical devices. Ransomware's effects continue to trouble the US Marshals Service. The US Justice Department shifts how it deals with large scale cybercrime. Fresh phish from the GRU. Caleb Barlow looks at unicorns and zombiecorns. Our guest Manoj Sharma from Symantec explains the differences between Zero Trust and SASE. And KillNet runs an ask-me-anything session. For links to all of today's stories check out our CyberWire daily news briefing: https://thecyberwire.com/newsletters/daily-briefing/12/83 Selected reading. Illumina cyber vulnerability may present risks for patient results (U.S. Food and Drug Administration) CISA, FDA warn of new Illumina DNA device vulnerability (Record Key law enforcement computers still down 10 weeks after breach (Washington Post) Feds Prioritizing Disruptions Over Arrests in Cyberattack Cases (PCMAG)  "Ashamed" LockBit ransomware gang apologises to hacked school, offers free decryption tool (Hot for Security)  APT28 cyberattack: distribution of emails with "instructions" on "updating the operating system" (CERT-UA#6562) (CERT-UA) Hackers use fake ‘Windows Update' guides to target Ukrainian govt (BleepingComputer)  Ukraine at D+431: Drone strikes and phishing expeditions. (CyberWire)

Character Database: Biomedical EngineerAmanda Randles is a computer scientist who is the Alfred Winborne and Victoria Stover Mordecai Professor of Biomedical Sciences at Duke University. Randles has been an assistant professor of biomedical engineering and computer science at the university and works at the Duke Cancer Institute. Her research includes biomedical simulation and high-performance computing.For the full uncut video (36mins) and access to our entire character database become a Monthly or Pro member at The Successful Screenwriter.--> https://www.thesuccessfulscreenwriter.com